107.53

0.77% -0.73

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $107.53, with a volume of 447.72K. It is down -0.77% in the last 24 hours and up +19.60% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Previous Close:

$108.26

Open:

$108.26

24h Volume:

447.72K

Relative Volume:

0.57

Market Cap:

$7.39B

Revenue:

$217.17M

Net Income/Loss:

$-202.68M

P/E Ratio:

-46.70

EPS:

-2.3028

Net Cash Flow:

$-156.63M

1W Performance:

+10.99%

1M Performance:

+19.60%

6M Performance:

-2.34%

1Y Performance:

+74.83%

1-Day Range:

$106.39

$111.09

1-Week Range:

$97.44

$111.71

52-Week Range:

$61.00

$122.20

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1103)

Industry

Biotechnology (619)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

414

Twitter

@rhythmpharma

Next Earnings Date

2026-08-04

Latest SEC Filings

RYTM's Discussions on Twitter

Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RYTM Rhythm Pharmaceuticals Inc	107.70	7.43B	217.17M	-202.68M	-156.63M	-2.3028
VRTX Vertex Pharmaceuticals Inc	487.09	121.87B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.20	65.01B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	882.45	55.26B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.70	39.14B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	179.32	37.88B	742.00K	-1.37B	-1.07B	-7.0731

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	RBC Capital Mkts	Outperform
Nov-25-25	Initiated	Citigroup	Buy
Nov-05-25	Downgrade	Oppenheimer	Outperform → Perform
Jul-10-25	Initiated	Goldman	Buy
Jul-07-25	Initiated	Leerink Partners	Outperform
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy
Mar-05-25	Resumed	Stifel	Buy
Jan-02-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Guggenheim	Buy
Sep-18-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	JMP Securities	Mkt Outperform
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

Jun 25, 2026

Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart

Jun 25, 2026

Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Canada

Jun 25, 2026

Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan

Jun 25, 2026

[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan

Jun 25, 2026

Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan

Jun 25, 2026

Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan

Jun 25, 2026

Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan

Jun 25, 2026

Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan

Jun 25, 2026

Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView

Jun 25, 2026

RYTM Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock - Moomoo

Jun 24, 2026

Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares - Stock Titan

Jun 24, 2026

8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24% - Trefis

Jun 24, 2026

Jun 23, 2026

Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative - Sahm

Jun 23, 2026

Jun 22, 2026

Rhythm Pharmaceuticals stock surges 4.98% as RhythmPharma announces Dr. Shoemaker joins as Senior Medical Director - Traders Union

Jun 22, 2026

Form 144 RHYTHM PHARMACEUTICALS For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

[144] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Jun 22, 2026

Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder? - Insider Monkey

Jun 22, 2026